On the contrary, the role of Delta16HER2 in driving the resistance to HER2- and EGFR-targeted therapies is supported not only by work done by our group using physiologically-relevant breast cancer models31,36, but also in HER2-positive gastric cancer patients and EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer39,40. This evidence concerns the gene EGFR and gastric cancer.